Case Report: Successful Treatment With Monoclonal Antibodies in One APDS Patient With Prolonged SARS-CoV-2 Infection Not Responsive to Previous Lines of Treatment.
Front Immunol
; 13: 891274, 2022.
Статья
в английский
| MEDLINE | ID: covidwho-1924105
ABSTRACT
We described the case of a patient affected by activated PI3K-kinase delta syndrome (APDS) and a long-lasting and pauci-symptomatic SARS-CoV-2 infection, treated with multiple therapeutic agents including remdesivir and SARS-CoV-2-neutralizing monoclonal antibodies. We detected the clearance of the virus 105 days from the first positive swab and 7 days after monoclonal antibody administration. At genotyping, the SARS-CoV-2 virus resulted as wild type on all samples tested. This case shows the monoclonal antibodies' good tolerability and efficacy in reducing viral shedding in long-lasting infections refractory to other treatments.
ключевые слова
Полный текст:
Имеется в наличии
Коллекция:
Международные базы данных
база данных:
MEDLINE
Основная тема:
COVID-19 Drug Treatment
Тип исследования:
История болезни
Темы:
Длинный Ковид
Пределы темы:
Люди
Язык:
английский
Журнал:
Front Immunol
Год:
2022
Тип:
Статья
Аффилированная страна:
Fimmu.2022.891274
Документы, близкие по теме
MEDLINE
...
LILACS
LIS